Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma

Abstract Background There is a need to develop new and more potent radiofluorinated peptide and their hybrid conjugates for multiple-receptors targeting properties that overexpress on many cancers. Methods We have synthesized MUC1-[18F] SFB and MUC1-FA-[18F] SFB hybrid conjugates using a convenient...

Full description

Bibliographic Details
Main Authors: I. Al Jammaz, B. Al-Otaibi, Y. Al-Malki, A. Abousekhrah, S. M. Okarvi
Format: Article
Language:English
Published: SpringerOpen 2021-03-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
Online Access:https://doi.org/10.1186/s41181-021-00127-y
id doaj-0e770066d9024060a0a8dfe55ff4da16
record_format Article
spelling doaj-0e770066d9024060a0a8dfe55ff4da162021-03-21T12:03:57ZengSpringerOpenEJNMMI Radiopharmacy and Chemistry2365-421X2021-03-016111710.1186/s41181-021-00127-yFast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinomaI. Al Jammaz0B. Al-Otaibi1Y. Al-Malki2A. Abousekhrah3S. M. Okarvi4Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research CentreCyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research CentreCyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research CentreCyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research CentreCyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research CentreAbstract Background There is a need to develop new and more potent radiofluorinated peptide and their hybrid conjugates for multiple-receptors targeting properties that overexpress on many cancers. Methods We have synthesized MUC1-[18F] SFB and MUC1-FA-[18F] SFB hybrid conjugates using a convenient and one-step nucleophilic displacement reaction. In vitro cell binding and in vivo evaluation in animals were performed to determine the potential of these radiolabeled compounds. Results Radiochemical yields for MUC1-[18F] SFB and MUC1-FA-[18F] SFB conjugates were greater than 70% in less than 30 min synthesis time. Radiochemical purities were greater than 97% without HPLC purification, which makes these approaches amenable to automation. In vitro studies on MCF7 breast cancer cells showed that the significant amounts of the radiofluorinated conjugates were associated with cell fractions and held good affinity and specificity for MCF7 cells. In vivo characterization in Balb/c mice revealed rapid blood clearance with excretion predominantly by urinary as well as hepatobiliary systems for MUC1-[18F] SFB and MUC1-FA-[18F] SFB, respectively. Biodistribution in SCID mice bearing MCF7 xenografts, demonstrated excellent tumor uptake (12% ID/g) and favorable kinetics for MUC1-FA-[18F] SFB over MUC1-[18F]SFB. The tumor uptake was blocked by the excess co-injection of cold peptides suggesting the receptor-mediated process. Conclusion Initial PET/CT imaging of SCID mice with MCF7 xenografts, confirmed these observations. These results demonstrate that MUC1-FA-[18F] SFB may be a useful PET imaging probe for breast cancer detection and monitoring tumor response to the treatment.https://doi.org/10.1186/s41181-021-00127-y18F-fluorination18F-fluoromucin 118F-fluorofolateHybrid-peptideBreast cancer
collection DOAJ
language English
format Article
sources DOAJ
author I. Al Jammaz
B. Al-Otaibi
Y. Al-Malki
A. Abousekhrah
S. M. Okarvi
spellingShingle I. Al Jammaz
B. Al-Otaibi
Y. Al-Malki
A. Abousekhrah
S. M. Okarvi
Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma
EJNMMI Radiopharmacy and Chemistry
18F-fluorination
18F-fluoromucin 1
18F-fluorofolate
Hybrid-peptide
Breast cancer
author_facet I. Al Jammaz
B. Al-Otaibi
Y. Al-Malki
A. Abousekhrah
S. M. Okarvi
author_sort I. Al Jammaz
title Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma
title_short Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma
title_full Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma
title_fullStr Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma
title_full_unstemmed Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma
title_sort fast fluorine-18 labeling and preclinical evaluation of novel mucin1 and its folate hybrid peptide conjugate for targeting breast carcinoma
publisher SpringerOpen
series EJNMMI Radiopharmacy and Chemistry
issn 2365-421X
publishDate 2021-03-01
description Abstract Background There is a need to develop new and more potent radiofluorinated peptide and their hybrid conjugates for multiple-receptors targeting properties that overexpress on many cancers. Methods We have synthesized MUC1-[18F] SFB and MUC1-FA-[18F] SFB hybrid conjugates using a convenient and one-step nucleophilic displacement reaction. In vitro cell binding and in vivo evaluation in animals were performed to determine the potential of these radiolabeled compounds. Results Radiochemical yields for MUC1-[18F] SFB and MUC1-FA-[18F] SFB conjugates were greater than 70% in less than 30 min synthesis time. Radiochemical purities were greater than 97% without HPLC purification, which makes these approaches amenable to automation. In vitro studies on MCF7 breast cancer cells showed that the significant amounts of the radiofluorinated conjugates were associated with cell fractions and held good affinity and specificity for MCF7 cells. In vivo characterization in Balb/c mice revealed rapid blood clearance with excretion predominantly by urinary as well as hepatobiliary systems for MUC1-[18F] SFB and MUC1-FA-[18F] SFB, respectively. Biodistribution in SCID mice bearing MCF7 xenografts, demonstrated excellent tumor uptake (12% ID/g) and favorable kinetics for MUC1-FA-[18F] SFB over MUC1-[18F]SFB. The tumor uptake was blocked by the excess co-injection of cold peptides suggesting the receptor-mediated process. Conclusion Initial PET/CT imaging of SCID mice with MCF7 xenografts, confirmed these observations. These results demonstrate that MUC1-FA-[18F] SFB may be a useful PET imaging probe for breast cancer detection and monitoring tumor response to the treatment.
topic 18F-fluorination
18F-fluoromucin 1
18F-fluorofolate
Hybrid-peptide
Breast cancer
url https://doi.org/10.1186/s41181-021-00127-y
work_keys_str_mv AT ialjammaz fastfluorine18labelingandpreclinicalevaluationofnovelmucin1anditsfolatehybridpeptideconjugatefortargetingbreastcarcinoma
AT balotaibi fastfluorine18labelingandpreclinicalevaluationofnovelmucin1anditsfolatehybridpeptideconjugatefortargetingbreastcarcinoma
AT yalmalki fastfluorine18labelingandpreclinicalevaluationofnovelmucin1anditsfolatehybridpeptideconjugatefortargetingbreastcarcinoma
AT aabousekhrah fastfluorine18labelingandpreclinicalevaluationofnovelmucin1anditsfolatehybridpeptideconjugatefortargetingbreastcarcinoma
AT smokarvi fastfluorine18labelingandpreclinicalevaluationofnovelmucin1anditsfolatehybridpeptideconjugatefortargetingbreastcarcinoma
_version_ 1724210950944325632